pharma · Hemophagocytic lymphohistiocytosis (HLH) · Multiple sclerosis
PARItec
Pari Pharma GmbH
Pari Pharma is a pharma organization headquartered in Starnberg, DE. Primary therapeutic focus areas include Hemophagocytic lymphohistiocytosis (HLH), Multiple sclerosis, Acute Myocardial Infarction, Familial Mediterrane
Starnberg, DE HQ
28 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Starnberg, DE
- Employees
- 28
- Programs
- 248
- Drugs
- 362
- Patents
- 0
APHP200056
Phase 3 · other · Remyelination in Multiple Sclerosis
APHP200056 for Remyelination in Multiple Sclerosis is a Phase 3 program (other) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).
Internal code APHP200056
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Pari Pharma GmbH
- Phase
- Phase 3
- Modality
- other
- Indication
- Remyelination in Multiple Sclerosis
- Status
- active
- Trials
- 1